Search Results - "Kopp, W C"

Impact of Weight Loss on Inflammatory Proteins and Their Association With the Insulin Resistance Syndrome in Morbidly Obese Patients by Kopp, H P, Kopp, C W, Festa, A, Krzyzanowska, K, Kriwanek, S, Minar, E, Roka, R, Schernthaner, G

“…OBJECTIVE—Obesity is closely linked to the insulin resistance syndrome (IRS), type 2 diabetes, and cardiovascular disease, the primary cause of morbidity and…”
Get full text

Inflammatory cytokines interleukin-6 and oncostatin M induce plasminogen activator inhibitor-1 in human adipose tissue by REGA, G, KAUN, C, ROEHLE, R, MAURER, G, HUBER, K, WOJTA, J, WEISS, T. W, DEMYANETS, S, ZORN, G, KASTL, S. P, STEINER, S, SEIDINGER, D, KOPP, C. W, FREY, M

“…Adipose tissue is a prominent source of plasminogen activator inhibitor-1 (PAI-1), the primary physiological inhibitor of plasminogen activation. Increased…”
Get full text

Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer by ZUJEWSKI, J, HORAK, I. D, KOPP, W. C, KOHLER, D. R, CHOW, C, NOONE, M, HAKIM, F. T, LARKIN, G, GRESS, R. E, NUSSENBLATT, R. B, KREMER, A. B, COWAN, K. H, BOL, C. J, WOESTENBORGHS, R, BOWDEN, C, END, D. W, PIOTROVSKY, V. K, CHIAO, J, BELLY, R. T, TODD, A

“…To determine the maximum-tolerated dose, toxicities, and pharmacokinetic profile of the farnesyl protein transferase inhibitor R115777 when administered orally…”
Get full text

Immune reactivity after adenoviral‐mediated aquaporin‐1 cDNA transfer to human parotid glands by Alevizos, I, Zheng, C, Cotrim, AP, Goldsmith, CM, McCullagh, L, Berkowitz, T, Strobl, SL, Malyguine, A, Kopp, WC, Chiorini, JA, Nikolov, NP, Neely, M, Illei, GG, Baum, BJ

“…Objectives The purpose of this study was to examine the humoral and cellular immune reactivity to adenoviral vector (AdhAQP1) administration in the human…”
Get full text

Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells by Hestdal, K, Ruscetti, FW, Ihle, JN, Jacobsen, SE, Dubois, CM, Kopp, WC, Longo, DL, Keller, JR

“…Murine bone marrow cells expressing the cell surface Ag RB6-8C5 were identified by fluorescence-activated cell-sorting analysis using a rat IgG mAb. The…”
Get full text

Adenosine diphosphate‐inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel by GREMMEL, T., STEINER, S., SEIDINGER, D., KOPPENSTEINER, R., PANZER, S., KOPP, C. W.

“…Background: Until recently, there were hardly any data on the antiplatelet effect of clopidogrel in advanced age. Like other metabolic processes, the…”
Get full text

In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation by Gremmel, T, Steiner, S, Seidinger, D, Koppensteiner, R, Panzer, S, Kopp, C W

“…Data linking the response to antiplatelet therapy with clinical outcomes after angioplasty and stenting for lower extremity artery disease (LEAD) are scarce…”
Get more information

Continuous Infusion of the Anti-CD22 Immunotoxin IgG-RFB4-SMPT-dgA in Patients With B-Cell Lymphoma: A Phase I Study by Sausville, Edward A., Headlee, Donna, Stetler-Stevenson, Maryalice, Jaffe, Elaine S., Solomon, Diane, Figg, William D., Herdt, Jean, Kopp, William C., Rager, Helen, Steinberg, Seth M., Ghetie, Victor, Schindler, John, Uhr, Jonathan, Wittes, Robert E., Vitetta, Ellen S.

“…lgG-RFB4-SMPT-dgA consists of deglycosylated ricin A chain (dgA) coupled to the monoclonal antihuman CD22 antibody, RFB4. This study determined the maximally…”
Get full text

Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer by Curti, B D, Ochoa, A C, Powers, G C, Kopp, W C, Alvord, W G, Janik, J E, Gause, B L, Dunn, B, Kopreski, M S, Fenton, R, Zea, A, Dansky-Ullmann, C, Strobl, S, Harvey, L, Nelson, E, Sznol, M, Longo, D L

“…We performed a phase I trial to determine whether in vivo expansion of activated CD4+ T cells was possible in cancer patients. 111Indium labeling was used to…”
Get more information

Xenogeneic endothelial cells activate human prothrombin by SIEGEL, J. B, GREY, S. T, LESNIKOSKI, B.-A, KOPP, C. W, SOARES, M, SCHULTE AM ESCH, J. II, BACH, F. H, ROBSON, S. C

“…Delayed xenograft rejection is characterized by platelet activation and fibrin deposition and is thought to occur independently of complement activation. We…”
Get full text

Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors by KOPP, C. W, SIEGEL, J. B, HANCOCK, W. W, ANRATHER, J, WINKLER, H, GECZY, C. L, KACZMAREK, E, BACH, F. H, ROBSON, S. C

“…Delayed xenograft rejection (DXR) is characterized by inflammation and vascular thrombosis. Activation of coagulation may occur as a result of tissue factor…”
Get full text

Effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies by Speiser, W, Kapiotis, S, Kopp, C W, Simonitsch, I, Jilma, B, Jansen, B, Exner, M, Chott, A

“…Inflammatory mediators were shown to exert procoagulant effects on cultured human endothelial cells (EC). In the present study the effect of intradermal…”
Get more information

Conditioned Immune Response to Interferon-γ in Humans by Longo, D.L., Duffey, P.L., Kopp, W.C., Heyes, M.P., Alvord, W.G., Sharfman, W.H., Schmidt, P.J., Rubinow, D.R., Rosenstein, D.L.

“…We determined whether a classical conditioning paradigm may be used to condition immunologic responses in normal human subjects receiving an optimal…”
Get full text

Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen by Stinson, S F, Alley, M C, Kopp, W C, Fiebig, H H, Mullendore, L A, Pittman, A F, Kenney, S, Keller, J, Boyd, M R

“…A panel of 60 human tumor cell lines is currently being used in the U.S. National Cancer Institute's in vitro anticancer drug screen. The panel is organized…”
Get more information

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer by Gause, B L, Sznol, M, Kopp, W C, Janik, J E, Smith, 2nd, J W, Steis, R G, Urba, W J, Sharfman, W, Fenton, R G, Creekmore, S P, Holmlund, J, Conlon, K C, VanderMolen, L A, Longo, D L

“…Although high-dose interleukin-2 (IL-2) can produce durable remissions in a subset of responding patients with renal cell carcinoma (RCC), this occurs in the…”
Get more information

Expression of human thrombomodulin cofactor activity in porcine endothelial cells by KOPP, C. W, GREY, S. T, SIEGEL, J. B, MCSHEA, A, VETR, H, WRIGHTON, C. J, AM ESCH, J. S, BACH, F. H, ROBSON, S. C

“…Xenograft rejection may predispose to vascular thrombosis because of putative cross-species' functional incompatibilities between natural anticoagulants…”
Get full text

Combined heart and kidney transplantation using a single donor: A single center's experience with nine cases by KOCHER, A. A, SCHLECHTA, B, LAUFER, G, KOPP, C. W, EHRLICH, M, ANKERSMIT, J, OFNER, P, LANGER, F, BERLAKOVICH, G. A, GRIMM, M, WOLNER, E

“…Simultaneous double-organ transplants comprising various organ combinations have become frequent. The purpose of this article is to report on a single center's…”
Get full text

Regulation of monocyte tissue factor activity by allogeneic and xenogeneic endothelial cells by Kopp, C W, Robson, S C, Siegel, J B, Anrather, J, Winkler, H, Grey, S, Kaczmarek, E, Bach, F H, Geczy, C L

“…The regulation of tissue factor (TF) activity by the cell associated tissue factor pathway inhibitor (TFPI) during monocyte (Mo) and endothelial cell (EC)…”
Get more information

Deoxycoformycin-Induced Immunosuppression in Patients With Hairy Cell Leukemia by Urba, Walter J., Baseler, Michael W., Kopp, William C., Steis, Ronald G., Clark, Jeffrey W., Smith II, John W., Coggin, David L., Longo, Dan L.

“…Immune function in patients with hairy cell leukemia (HCL) was examined serially during treatment with alternating monthly cycles of recombinant interferon…”
Get full text

Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer by W C Kopp, W J Urba, H C Rager, W G Alvord, J J Oppenheim, J W Smith, 2nd, D L Longo

“…The interleukin 1 receptor antagonist (IL-1ra) is a naturally occurring molecule that shares homology with IL-1alpha and IL-1beta and binds competitively to…”
Get full text